Oncolytics Biotech Inc (ONCY)

NASDAQ
Currency in USD
0.791
-0.048(-5.96%)
Closed
After Hours
0.800+0.009(+1.138%)
ONCY Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
Day's Range
0.7820.830
52 wk Range
0.7101.530
Key Statistics
Edit
Prev. Close
0.839
Open
0.82
Day's Range
0.782-0.83
52 wk Range
0.71-1.53
Volume
1.65M
Average Vol. (3m)
1.03M
1-Year Change
-34.63%
Book Value / Share
0.09
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ONCY Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash
Show more

Oncolytics Biotech Inc Company Profile

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

Oncolytics Biotech Inc SWOT Analysis


Analyst Outlook
RBC Capital Markets maintains a $6 price target with an Outperform rating, highlighting pela's potential while acknowledging the speculative nature of the investment
Financial Tightrope
Despite a healthy current ratio, Oncolytics faces cash burn challenges. Efficient trial designs may help conserve resources as the company advances without immediate partnerships
Regulatory Tailwinds
FDA's support for progression-free survival as a primary endpoint could accelerate pela's path to market, potentially streamlining the approval process
Pela's Promise
Oncolytics Biotech's lead candidate, pela, shows potential in metastatic breast cancer and pancreatic cancer, driving speculative interest in this clinical-stage company
Read full SWOT analysis

Oncolytics Biotech Inc Earnings Call Summary for Q2/2024

  • Oncolytics Biotech advances pelareorep in breast and pancreatic cancer trials; FDA meeting held to discuss breast cancer development path
  • First patient dosed in modified GOBLET study for pancreatic cancer; BRACELET-1 trial overall survival results expected later this year
  • Strong financial position with $24.9M cash and runway into 2025; collaborating with GCAR on adaptive registration enabling trial for pancreatic cancer
  • Phase 2/3 registration trial in breast cancer to enroll patients who failed ADC therapy; potential for second registrational study from GOBLET cohort 5
  • Company on track for multiple milestones, focusing on advancing pelareorep toward registrational studies in breast and pancreatic cancers
Last Updated: 08/02/2024, 04:46 PM
Read Full Transcript

Compare ONCY to Peers and Sector

Metrics to compare
ONCY
Peers
Sector
Relationship
P/E Ratio
−3.2x−4.7x−0.6x
PEG Ratio
−0.120.030.00
Price / Book
9.9x−4.2x2.6x
Price / LTM Sales
-3.4x3.1x
Upside (Analyst Target)
-156.3%53.6%
Fair Value Upside
Unlock−17.0%8.0%Unlock

Earnings

Latest Release
Nov 12, 2024
EPS / Forecast
-0.12 / -0.10
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

FAQ

What Is the Oncolytics Biotech (ONCY) Stock Price Today?

The Oncolytics Biotech stock price today is 0.791

What Stock Exchange Does Oncolytics Biotech Trade On?

Oncolytics Biotech is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for Oncolytics Biotech?

The stock symbol for Oncolytics Biotech is "ONCY."

What Is the Oncolytics Biotech Market Cap?

As of today, Oncolytics Biotech market cap is 61.48M.

What is Oncolytics Biotech Earnings Per Share?

The Oncolytics Biotech EPS is -0.366.

What Is the Next Oncolytics Biotech Earnings Date?

Oncolytics Biotech will release its next earnings report on Mar 06, 2025.

From a Technical Analysis Perspective, Is ONCY a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.